R&D Data and Investment

 

R&D costs have being stable throughout the years, totaling a 5% of total revenues. This amount of investment in R&D is sufficient to guarantee us the launch or 6 to 8 immunoassays a year with the addition of the new Molecular Diagnostics tests. We are the Company that is launching the highest number of tests per year in the market, maintaining the highest quality standards on every product.

This product launch rate demands our sales and marketing people a big effort to reach all of our clients and new ones with old and new products. Furthermore, when a new test is launched on the market, it also needs to be registered in the various destination countries where the local authority needs to approve the quality of the product according to its standards. Up to now our products are not all registered in every country of operation, therefore revenues increases depend not only on the launch of brand new products on the market, but also on new registrations.
For all these reasons, spending 5% of revenues on R&D guarantees DiaSorin with a good balance between the launch many new products on the market and the ability to keep costs under control.

 

 

  

 

2012

2013 

2014

Research and development costs that were not capitalized

21,577

22,013

22,642

Annual amortization of capitalized costs

1,816

1,934

2,352

Total research and development costs charged to income

23,393

23,947

24,994

Development costs capitalized during the year

3,323

2,616

1,401

Total research and development costs

24,900

24,629

24,043